Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease

Yoseph Shaaltiel, Svetlana Gingis-Velitski, Salit Tzaban, Nadia Fiks, Yoram Tekoah, David Aviezer

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Gaucher's disease (GD), a lysosomal storage disorder caused by mutations in the gene encoding glucocerebrosidase (GCD), is currently treated by enzyme replacement therapy (ERT) using recombinant GCD that is administered intravenously every 2 weeks. However, intravenous administration includes discomfort or pain and might cause local and systemic infections that may lead to low patient compliance. An orally administered drug has the potential to alleviate these problems. In this study, we describe the potential use of plant cells as a vehicle for the oral delivery of recombinant human GCD (prGCD) expressed in carrot cells. The in vitro results demonstrate that the plant cells protect the recombinant protein in the gastric fluids and may enable absorption into the blood. Feeding experiments, with rat and pig as model animals, using carrot cells containing prGCD, show that active recombinant prGCD was found in the digestive tract and blood system and reached both, liver and spleen, the target organs in GD. These results demonstrate that the oral administration of proteins encapsulated in plant cells is feasible. Specifically, carrot cells containing recombinant human prGCD can be used as an oral delivery system and are a feasible alternative to intravenous administration of ERT for GD.

Original languageEnglish
Pages (from-to)1033-1040
Number of pages8
JournalPlant Biotechnology Journal
Issue number8
StatePublished - 1 Oct 2015

Bibliographical note

Publisher Copyright:
© 2015 Society for Experimental Biology, Association of Applied Biologists and John Wiley & Sons Ltd.


  • Enzyme replacement therapy
  • Gaucher's disease
  • Lysosomal storage disorder
  • Oral delivery
  • Plant cells
  • β-glucocerebrosidase


Dive into the research topics of 'Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease'. Together they form a unique fingerprint.

Cite this